Corcept Therapeutics is trading 6.07% up after hours at $91.17 on October 29, with no verified company-specific announcement explaining the rise. - Regular-session close: $85.95; data shows a sharp rebound after recent losses, but not why. - The Nasdaq Composite fell 2.32% and the S&P 500 fell 0.91%; available context does not indicate Corcept’s rise tracked the market. - Latest identified announcements were positive Phase 2 BELLA results on October 26 and a November 3 earnings date; neither is confirmed as the catalyst. After-hours volume was not provided.